# CRB-701

Source: https://onco.cc/drugs/crb-701/  
OnCo record `crb-701` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CRB-701 is an experimental antibody-drug conjugate from Corbus Pharmaceuticals in phase 2 trials, aimed at Nectin-4.

## Summary

CRB-701 is an antibody-drug conjugate developed by Corbus Pharmaceuticals. Its target is Nectin-4 (the sponsor names Nectin-4). ClinicalTrials.gov describes the intervention as: Nectin-4 targeted Antibody Drug Conjugate (ADC). It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial. The largest, NCT06265727, plans to enrol 348 participants with primary completion expected 2027-01-16. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: ADC
- Mechanism: Antibody-drug conjugate directed at Nectin-4, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of CRB-701: https://clinicaltrials.gov/search?intr=CRB-701
- Sponsor page: https://www.corbuspharma.com

## Connected records

- targets: [Nectin-4](https://onco.cc/targets/nectin4/)
- companies: [Corbus Pharmaceuticals](https://onco.cc/companies/corbus-pharmaceuticals/)
- trials: [A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors](https://onco.cc/trials/nct06265727/)

---
JSON: https://onco.cc/api/v1/entities/crb-701.json